# Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

> **NCT05768854** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 69 (actual)

## Conditions studied

- Osteogenesis Imperfecta

## Interventions

- **DRUG:** Bisphosphonate
- **BIOLOGICAL:** Setrusumab

## Key facts

- **NCT ID:** NCT05768854
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-14
- **Primary completion:** 2025-10-23
- **Final completion:** 2027-04
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05768854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05768854, "Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05768854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*